Objective To explore the effect of apatinib on the thyroid function in patients with malignant tumors. Methods The clinical data of 15 patients with advanced malignant neoplasm were retrospectively analyzed. The patients were all administered apatinib. The thyroid function was detected before and after treatment. The incidence of abnormal thyroid function was assessed after one month of treatment. Results At one month after treatment,hypothyroidism occurred in 12(80. 0% ) out of 15 patients with advanced malignant tumors. The median time from taking medicine to the occurrence of abnormal thyroid function was 32. 3 days. Among 12 patients with abnormal thyroid function,decreased thyroid stimulating hormone(TSH) level was observed in 2 patients after drug withdrawal;increased TSH level was observed in 3 patients after continuing taking apatinib,and clinical hypothyroidism occurred in 1 patient with subclinical hypothyroidism. Conclusion The incidence rate of hypothyroidism due to apatinib is quite high and may be severe,therefore,clinical attention and early intervention should be performed.%目的 探讨阿帕替尼对恶性肿瘤患者甲状腺功能的影响.方法 回顾性分析15例晚期恶性肿瘤患者的临床资料,患者均接受阿帕替尼治疗,治疗前后进行甲状腺功能检测,分析治疗1个月后甲状腺功能异常发生情况.结果 15例晚期恶性肿瘤患者使用阿帕替尼治疗1个月后,共12例患者(80. 0% )出现甲状腺功能减退,用药至出现甲状腺功能异常的中位时间为32. 3 d. 12例甲状腺功能异常患者中,3例患者停止用药后促甲状腺激素(TSH)水平下降;3例患者继续使用阿帕替尼,TSH值均出现进行性升高(其中1例亚临床甲状腺功能减退患者发展为临床型甲状腺功能减退).结论 阿帕替尼致甲状腺功能减退的发生率较高,病情较严重,应引起临床重视并及早干预.
展开▼
